Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Slingshot Biosciences Announces Election of Nicolas Barthelemy as Executive Chair


Slingshot Biosciences Inc., a leader in the development of cell mimics for cell therapy, diagnostics, and rare disease research, is proud to announce the addition of Nicolas Barthelemy as its Executive Chair. "We have been working closely with Nicolas over the last two years and are excited to bring his experience, operational expertise, and strategic insights to bear on this next phase of our growth," said Dr. Jeffrey Kim - CEO & President of Slingshot Biosciences. Dr. Kim added, "He has been a trusted partner in getting the company to where it is, today, and will continue to be a key member of our extended team as we scale the business to help patients worldwide."

Mr. Barthelemy's appointment comes at a crucial time as Slingshot is scaling its groundbreaking technologies in the biopharma sector, where he brings a long history of leadership in operating roles. His past experience includes Senior Management positions at leading companies in the sector, including Biogen and Life Technologies, where he held the position of Chief Commercial Officer. Nicolas also currently holds board positions at Repligen, Inc., Biocare Medical, and Nanocellect.

"I am very excited to step-up my involvement with such a talented team at a pivotal time of its journey, and at the 'ground level' of a technology as potentially disruptive as Slingshot Biosciences' novel synthetic cells. With end-applications ranging from Research and Bioprocessing to Hematology, Diagnostics and Therapeutics, we have the opportunity to build a company that could meaningfully impact a very broad area of Life Sciences," said Nicolas Barthelemy.

Nicolas received an Engineering Degree from ESPCI (Paris, France) and an M.S. in Chemical Engineering from UC Berkeley.

About Slingshot Biosciences

At the cutting edge of cell engineering technology, Slingshot Biosciences is revolutionizing cell therapy development and manufacturing. The company's pioneering work in creating cell mimics positions it uniquely to help advance research, diagnostics and biopharma manufacturing. Slingshot's products offer more consistent, scalable, and ethically viable alternatives to traditional methods of cell-based sourcing.


These press releases may also interest you

at 04:09
China and Kazakhstan have always supported each other and have always been partners in times of challenges, Chinese President Xi Jinping said in a signed article in the Kazakhstanskaya Pravda newspaper and Kazinform International News Agency on...

at 04:05
H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with $64 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to acquire CGH Group S.A. ("CGH" or the "Company"), a...

at 03:55
The International Nut and Dried Fruit Council (INC), conducted an extensive study on Latin America's Gen Z dietary...

at 03:44
Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, is publishing its interim report for January-June on Friday 19 July 2024 at 07.30 CET.  Alan Mamedi, CEO and Odd Bolin, CFO presents the report and...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:09
China and Kazakhstan have always supported each other and have always been partners in times of challenges, Chinese President Xi Jinping said in a signed article in the Kazakhstanskaya Pravda newspaper and Kazinform International News Agency on...



News published on and distributed by: